Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues

Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results...

Related Keywords

Michigan ,United States ,Texas ,Zack Irani ,Beth Israel Deaconess Medical Center Inc ,Company Covid ,Harvard Medical School ,Biomerica Inc ,Nasdaq ,University Of Michigan ,Abdominal Pain Intensity ,Chief Executive Officer ,Mayo Clinic ,Beth Israel Deaconess Medical Center ,Houston Methodist ,Texas Health Science Center ,Nasdaq Bmra ,Biomerica ,Nc ,Irritable Bowel Syndrome ,Jobs ,Clinical Trial Results ,Bs Therapy ,Mayo ,